United States · Platforms & data · Yahoo Finance

Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

Published by Yahoo Finance · United States 8 h ago

Arcus Biosciences has pulled back sharply in recent weeks, even though investors are still digesting fresh trial data and a sizeable equity raise. For anyone looking at the stock…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Seeking Alpha

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M

Morningstar

Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

Share

Also worth reading

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Insider trades: Blackberry, Accenture and Cleveland-Cliffs among notable names

Woori Financial ADR earnings beat by $0.29, revenue topped estimates

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M

Market News